Resume of the Inventor – Mehmet Ali Söylemez, MD

    

PRIMARY LOCATION:
ISTANBUL-TURKEY

Position
CLINICAL GENETICIST

Residency
MARMARA UNIVERSITY, SCHOOL OF MEDICINE

Visitor for Medical Research
HARVARD MEDICAL SCHOOL COUNTWAY LIBRARY OF MEDICINE

Medical School
ISTANBUL UNIVERSITY, SCHOOL OF MEDICINE

Every Diabetic patient and their family are different, with own unique needs. My scientific goal is to design an individual diagnostic treatment plan to help each and every one of diabetic patients to achieve the best outcome possible.’

    I aim to make difference by empowering healthcare professionals in their clinical decision making, ultimately leading to improved patient care and reduced healhcare costs.

E-Mail :
Phone (Office) :
Phone (Cell):
mehmetali@diabeticbiomarker.com
+90 216 3428818
+90 537 2264452      

Memberships in Scientific Associations

  1. TURKISH MEDICAL GENETICS ASSOCIATION
  2. AMERICAN SOCIETY OF CELL AND GENE THERAPY
  3. EUROPEAN SOCIETY OF HUMAN GENETICS
  4. AMERICAN SOCIETY OF HUMAN GENETICS

AWARDS

  1. EUROPEAN SOCIETY OF HUMAN GENETICS; FELLOWSHIP AWARD, 2011, AMSTERDAM- NETHERLAND.
  2. GHP– GLOBAL The HEALTHCARE and PHARMACEUTICAL Award Winner in 2023STAFFORDSHIRE, UNITED KINGDOM.
  3. CIO BULLETIN INNOVATION EXCELLENCE AWARD Winner in 2024, NEW JERSEY-UNITED STATES OF AMERICA.
  4. THE SILICON REVIEW 30 FABULOUS COMPANY 2024 AWARD . 30 FABULOUS INVENTION AWARD WINNER IN 2024, NEW JERSEY- UNITED STATES OF AMERICA.
  5. The MOST SUCCESSFUL BUSINESS LEADERS to WATCH in 2024 , COLUMBUS-UNITED STATES OF AMERICA. https://theenterpriseworld.com/dr-mehmet-ali-soylemez/
Dr. Mehmet Ali Soylemez: Revolutionizing the Healthcare Industry | The Enterprise World
  1. This invention is also submitted a proposal for the LASKER AWARD 2024 and HARVARD MEDICAL SCHOOL ‘WARREN ALPERT PRIZE’ 2024 and EUROPEAN INVENTOR AWARD 2024.

2024 INNOVATION EXCELLENCE AWARD WINNERS

PATENT APPLICATIONS

1.    Procalcitonin Gene Expression As a Precise Biomarker Of Aging Process, Patent No: US 20130252254 A1  USPTO(United States Patent And Trademark OFFICE)

2.    Diagnosis And Complication Risk Assessment Of Pancreatic Diabetes Using Procalcitonin. Patent No: US 20110263438 A1  USPTO(United States Patent And Trademark OFFICE)

GRANTED PATENTS

Diagnosis of Pancreatic Diabetes in Patients with Normal Blood Leucocyte Counts Using Procalcitonin. Patent No: EP 2626704B1 EPO (European Patent Office)